Amendments to the Claims

Listing of Claims:

Claim 1 (currently amended): Use of A method of treating a mammal suffering from uveal melanoma comprising administering to said mammal in need of such a treatment, a dose, effective against said disease a Compound I of the following formula

or a pharmaceutically acceptable salt thereof. for the manufacture of a medicament for the treatment of uveal melanoma.

Claim 2 (currently amended): The <u>use-method</u> according to claim 1 wherein the uveal melanoma is a metatazing uveal melanoma.

Claim 3 (currently amended): The <u>use-method</u> according to claim 1 wherein the uveal melanoma expresses c-kit.

Claim 4 (currently amended): The <u>use-method</u> according to claim 1 wherein Compound I is in the form of the monomethanesulfonate salt.

Claim 5 (currently amended): The <u>use-method</u> according to claim 4 wherein the monomethanesulfonate salt of Compound I is in the beta crystal form.

Claim 6 (currently amended): The <u>use-method</u> according to claim 1 wherein Compound I is administered at a daily dose corresponding to 100 mg to 1000 mg of Compound I free base.

Claim 7 (currently amended): The <u>use-method</u> according to claim 6 wherein Compound I is administered once daily for a period exceeding 3 months.

Claim 8 (canceled)

Claim 9 (original): Use of a c-kit inhibitor or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of uveal melanoma.

Claim 10 (original): Use according to claim 9 wherein the uveal melanoma is a metastazing uveal melanoma.